Preview Mode Links will not work in preview mode

This Week in Cardiology

Dec 2, 2022

SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I. EMPA Kidney

- EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD

- EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease

- Empagliflozin in Patients with Chronic Kidney Disease

- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

- Dapagliflozin in Patients with Chronic Kidney Disease

- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

II. Publishing Choices

- Motorcycle Rallies Linked to Spike in Organ Transplants

- Organ Donation and Transplants During Major US Motorcycle Rallies

III. Second and Third Order Effects

- Heart Disease Deaths Spiked During COVID After 10-Year Decline

IV. Decision Support

- Patient App Aids Decisions on Anticoagulants: ENHANCE-AF

- A Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision‐Making Pathway

V. Percutaneous Left Atrial Appendage Closure

- Consider Life Expectancy When Referring for LAA Closure?

- Transcatheter Left Atrial Appendage Occlusion: A Multi-Center Real Life Experience

- Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure

- Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact